Author: admin

Plant Operations Improve Through Outsourced Accounts Payable Services as IBN Technologies Assists USA Firms

“IBN Technologies [USA]”
Manufacturers adopt outsourced accounts payable services to eliminate workflow disruption, reduce bottlenecks, and gain financial clarity. External service providers deliver invoice validation and payment tracking to reinforce operational balance and supplier confidence.

Miami, Florida, 04 Aug 2025 Manufacturing plants throughout the country are experiencing renewed financial stability as back-end systems adapt to higher production volumes. Payment coordination and invoice tracking have become more complex, encouraging many firms to outsourced accounts payable services for consistency and faster approvals. With expert help from companies such as IBN Technologies, U.S. factories are stabilizing their disbursement functions and keeping pace with procurement activity.

After initiating a full-scale accounts payable audit, some firms have identified inefficiencies tied to outdated verification routines or irregular payment schedules. Leveraging external AP support helps resolve those issues quickly, allowing teams to re-focus on supply chain execution. The benefits extend to enhanced vendor relations, reduced payment cycle variability, and cleaner reconciliation—outcomes that support plant performance without disrupting operations.

Eliminate payment delays with proven AP strategies

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-ap-ar-management/

Escalating Costs Disrupt AP

U.S. manufacturers are facing renewed cost instability due to inflation, leaving less room for financial missteps. Paper-driven AP workflows are adding friction just as vendor terms tighten, and payment expectations grow sharper.

▪ Human errors slowing down invoice processing

▪ Supplier penalties from overdue accounts

▪ Disconnected view of payables aging

▪ Internal approval queues creating drag

▪ Uncontrolled instances of repeat payments

▪ Struggles to respond to supplier changes

In response, organizations are consulting financial services firms to improve control and reduce overheads. Experts note that outsourced accounts payable services allow teams to manage disbursements with better structure and speed, supporting both supplier continuity and production momentum.

Payment Systems Improve Internally

Hospitality finance teams are refining their processes with external guidance and operational support. With guest demand rising, back-end consistency is now essential—and organizations are outsourcing functions to stay ahead.

✅ Managed invoice intake with multi-location hospitality supplier validation

✅ Timely processing schedules linked to agreed vendor arrangements

✅ End-to-end visibility into expense documents and cash outflows

✅ Immediate handling of unmatched entries and payment gaps

✅ Periodic ledger review support to ensure systemwide accuracy

✅ Staff coordination assistance for multi-department payment handling

✅ Secure vendor records and credential maintenance workflows

✅ Digitally archived payables for accurate tax season readiness

✅ Payment error checks included in review-before-release processes

✅ Scheduled exception follow-ups with structured response windows

Many decision-makers have turned to outsourced accounts payable services in Texas, partnering with experienced providers such as IBN Technologies. These firms bring consistent support, strategic structure, and proven guidance to strengthen AP outcomes.

Texas Manufacturing Accelerates AP Results

Texas-based manufacturers are simplifying financial operations and improving payment systems by integrating specialized support. The results show stronger internal controls, reduced delays, and increased vendor confidence. IBN Technologies continues to deliver structured solutions for regional production companies.

✅ Invoice cycle time cut, leading to 40% better cash flow.

✅ Internal workloads decline due to streamlined approval systems.

✅ Vendor reliability improves through consistent settlement scheduling.

With outsourced accounts payable services in Texas, manufacturers align finance with operations. IBN Technologies helps businesses optimize disbursements and maintain smooth vendor coordination.

Reinventing AP for Future Success

U.S. manufacturers are actively modernizing their financial operations to meet the demands of today’s complex supply networks. Invoice volumes have grown substantially, and vendor expectations have made clear, uninterrupted payment workflows an operational priority. Many firms are responding by implementing refined financial models that offer consistency, reduce administrative drag, and establish scalable routines. Businesses are setting measurable goals around accuracy, supplier trust, and processing clarity—replacing dated approaches with service-backed systems aligned to production performance and finance oversight.

Organizations that outsource accounts payable services are redesigning their Accounts Payable process into a fully guided function—supported by reliable documentation, structured oversight, and accurate reconciliation. Service providers such as IBN Technologies deliver adaptable support packages that reduce bottlenecks and maintain vendor satisfaction without increasing internal workload. By transitioning to expert-driven financial systems, manufacturers are strengthening long-term payment discipline, eliminating redundancies, and keeping teams focused on core output. Results have included cleaner audit preparation, faster disbursements, and clearer internal communication around liabilities—leading to more consistent vendor relationships and better resource planning.

Related Service:    

AP and AR Automation Services: https://www.ibntech.com/ap-ar-automation/     

About IBN Technologies                       

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.                       

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Plant Operations Improve Through Outsourced Accounts Payable Services as IBN Technologies Assists USA Firms

IBN Technologies Tax Preparation Service Demand Climbs as U.S. Firms Rethink Compliance Strategy

“Tax Preparation Service [USA]”
Businesses facing mounting regulatory pressure and multi-jurisdictional tax complexity are turning to tax preparation services for precision, continuity, and compliance. As policy changes accelerate, providers like IBN Technologies offer tailored tax solutions that align financial operations with current laws, helping companies maintain strategic oversight and avoid costly missteps.

Miami, Florida, 04 Aug 2025 Corporate leaders navigating heightened inflation and evolving tax policies are increasingly turning to specialized Tax preparation services for financial clarity and risk mitigation. The added complexity of operating across multiple jurisdictions has made it difficult for internal teams to manage filings, stay compliant, and interpret frequent policy changes.

The growing demand signals a larger movement toward proactive financial stewardship. Firms such as IBN Technologies are providing structured support through customized tax preparation frameworks tailored to each organization’s financial architecture. In a market where tax management now informs broader fiscal strategy, companies are redefining compliance as a continuous, high-stakes function.

Explore smarter tax preparation service for better compliance.

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-tax-return/

Finance Teams Feel the Pressure as Regulatory Demands Mount

With inflation on the rise and tax regulations becoming increasingly complex, finance departments across U.S. businesses are under growing strain. As the tax season approaches, internal systems are being tested, especially within organizations lacking specialized external support. In response, many companies are turning to tax management services to handle the surge in compliance requirements and maintain operational stability.

• Tight internal capacity as tax deadlines loom

• Outdated manual processes leading to bottlenecks

• Increased risk of errors due to intricate filing obligations

• Difficulty keeping pace with evolving tax laws

• Rising costs associated with short-term staffing solutions

Finance teams are finding it increasingly difficult to meet tax obligations amid rising workloads and regulatory shifts. Reliance on manual systems not only slows operations but also heightens the chance of costly mistakes. To ensure compliance and stay on schedule, more businesses are leveraging professional bookkeeping and tax service. These services enhance accuracy, reduce internal pressure, and allow teams to stay focused on core financial functions. As reporting demands peak, outsourcing is proving to be a dependable and strategic option.

Smarter Tax Filing Strategies for a Demanding Season

As tax season intensifies, businesses across the U.S. are re-evaluating their compliance strategies. Traditional in-house, manual processes are proving inadequate in a landscape shaped by constant regulatory updates and mounting complexity. To stay ahead, many companies are turning to outsourced tax preparation services for small business—prioritizing accuracy, timeliness, and efficiency over outdated methods. This shift is not merely about convenience, it’s about protecting operations, minimizing errors, and streamlining financial workflows during peak filing periods.

✅ Direct access to experienced professionals with current regulatory expertise

✅ Faster turnaround times during critical tax windows

✅ Significant reduction in internal workload and process delays

✅ Transparent progress tracking with real-time project visibility

✅ Strengthened compliance through multi-tier review and audit-ready practices

✅ Secure handling of all sensitive financial and personal data

✅ Scalable service options for both seasonal and ongoing requirements

✅ Lower operational costs by minimizing temp hiring and reducing errors

✅ Full compliance with both federal and local tax changes

✅ Centralized validation systems to ensure audit readiness and accuracy

Outdated manual systems are quickly becoming a risk factor for businesses as tax regulations grow more intricate and filing demands intensify. Internal finance teams are under pressure, often lacking the resources and tools to manage complex requirements efficiently. As a result, many organizations are turning to tax outsourcing services for reliable support. These services bring the expertise and infrastructure needed to ensure accurate, timely filings while relieving internal teams of operational strain.

IBN Technologies is addressing these challenges with end-to-end tax preparation service solutions tailored to a variety of entities. Their offerings include tax filings for individuals (Forms 1040, 1040A, 1040EZ, 1040NR), partnerships (Form 1065), corporations (Forms 1120, 1120S), estates and trusts (Form 1041), non-profits (Form 990), and gift tax requirements (Forms 706/709). These services not only reduce the risk of errors but also support regulatory compliance and save valuable time. For many businesses, outsourcing tax preparation service has become a strategic move—ensuring accuracy, maintaining continuity, and improving efficiency in today’s complex tax environment.

Precision-Focused Tax Solutions for Reliable Compliance

IBN Technologies provides dependable, scalable accounting and tax resolution services trusted by businesses nationwide. With more than two decades of industry experience, the firm is committed to delivering accurate, compliant, and timely tax filing support tailored to meet a wide range of client requirements.

✅ Over 26 years of expertise in tax and accounting outsourcing

✅ Serving 1,500+ clients across the U.S., UK, and Middle East

✅ Handles 50+ million transactions annually with consistent accuracy

✅ Maintains 99.99% filing accuracy through rigorous multi-level review

✅ ISO 9001 and ISO 27001 certified for quality management and data security

Proven Gains in Tax Compliance and Efficiency Businesses in the U.S. using outsourced tax preparation service are seeing clear improvements in compliance, accuracy, and efficiency. With expert support, they’re managing complex filings more effectively, especially during busy tax seasons.

• A U.S. e-commerce firm improved multi-state filings and reporting accuracy.

• A New Jersey firm streamlined tax processes after moving to QuickBooks.

• Several businesses met tight deadlines with fewer errors and no extra staff.

As tax rules grow more complex, outsourcing has become a smart, strategic move—offering scalable, accurate, and timely support throughout the tax cycle.

Future-Ready Tax Strategy Through Trusted Outsourcing

As regulatory demands continue to evolve, the role of outsourced tax preparation service is expected to grow even more critical. Businesses are increasingly seeking partners who can offer not just compliance support, but also strategic insights and operational flexibility. The future of tax preparation service lies in precision-driven services that can adapt quickly to changing legislation while maintaining accuracy, transparency, and efficiency. This shift underscores the importance of choosing service providers with a proven track record, robust infrastructure, and industry-specific knowledge.

In this evolving landscape, companies aiming to stay agile and compliant are turning to trusted outsourcing partners as a long-term strategy. By working with solution providers like IBN Technologies, businesses gain access to comprehensive, end-to-end tax preparation service support that aligns with both regulatory expectations and operational needs. Backed by decades of experience, high-accuracy processing, and scalable service delivery, IBN Technologies enables organizations to manage risk effectively, streamline compliance, and future-proof their financial operations.

Related Services:                

About IBN Technologies                            

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.                                                     

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IBN Technologies Tax Preparation Service Demand Climbs as U.S. Firms Rethink Compliance Strategy

Spinal Muscular Atrophy Pipeline Outlook 2025: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

“Spinal Muscular Atrophy Pipeline”
Spinal Muscular Atrophy companies are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others.

(Albany, USA) “Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To know more in detail about Spinal Muscular Atrophy pipeline report offerings, click here: Spinal Muscular Atrophy Clinical Trials and Pipeline

 

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

  • In July 2025, Hoffmann-La Roche announced results of a Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
  • In July 2025, Lantu Biopharma announced results of a Study of AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy in Subjects With Progressive Spinal Muscular Atrophy
  • In July 2025, Biogen announced results of an Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx™ System (PIERRE-PK)
  • In July 2025, GeneCradle Inc announced results of a Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
  • In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA
  • Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
  • Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment
  • Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
  • In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.
  • In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®).
  • On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy
  • On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.
  • On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children’s Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C).
  • On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®).
  • On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy
  • On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study.
  • On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA)

 

To know in detail about the Spinal Muscular Atrophy clinical trials and recent FDA approvals for Spinal Muscular Atrophy drugs, click here: Spinal Muscular Atrophy Drugs and Therapies

 

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression.

Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening.

Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life.

Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA.

 

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

  • Spinal Muscular Atrophy Assessment by Product Type
  • Spinal Muscular Atrophy By Stage and Product Type
  • Spinal Muscular Atrophy Assessment by Route of Administration
  • Spinal Muscular Atrophy By Stage and Route of Administration
  • Spinal Muscular Atrophy Assessment by Molecule Type
  • Spinal Muscular Atrophy by Stage and Molecule Type

 

DelveInsight’s Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

  • ACTX-401: Novartis
  • Apitegromab: Scholar Rock
  • GYM329: Roche
  • And Many Others

 

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Assessment- Spinal Muscular Atrophy Medication

 

Spinal Muscular Atrophy Pipeline Analysis:

  • The Spinal Muscular Atrophy pipeline report provides insights into
  • The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
  • Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.
  • The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs

 

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

  • Coverage: Global
  • Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others
  • Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
  • Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
  • Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

 

Request for Sample Report @ Spinal Muscular Atrophy Pipeline Outlook

 

Table of Contents

  • Spinal Muscular Atrophy Report Introduction
  • Spinal Muscular Atrophy Executive Summary
  • Spinal Muscular Atrophy Overview
  • Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
  • Spinal Muscular Atrophy Pipeline Therapeutics
  • Spinal Muscular Atrophy Late Stage Products (Phase II/III)
  • Spinal Muscular Atrophy Mid Stage Products (Phase II)
  • Spinal Muscular Atrophy Early Stage Products (Phase I)
  • Spinal Muscular Atrophy Preclinical Stage Products
  • Spinal Muscular Atrophy Therapeutics Assessment
  • Spinal Muscular Atrophy Inactive Products
  • Company-University Collaborations (Licensing/Partnering) Analysis
  • Spinal Muscular Atrophy Key Companies
  • Spinal Muscular Atrophy Key Products
  • Spinal Muscular Atrophy Unmet Needs
  • Spinal Muscular Atrophy Market Drivers and Barriers
  • Spinal Muscular Atrophy Future Perspectives and Conclusion
  • Spinal Muscular Atrophy Analyst Views
  • Appendix
  • About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Pipeline Outlook 2025: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

Lymphangioleiomyomatosis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

“Lymphangioleiomyomatosis Treatment Market”
Lymphangioleiomyomatosis Companies are Apotex Inc., Amneal Pharmaceuticals LLC, Dr. Reddy’s Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Zydus Pharmaceuticals, Inc, TransMedics, Inc., Terumo Corporation, Home Oxygen Company, Inogen, Inc., CareDx, XVIVO, Taj Pharmaceuticals Limited, Morgan Scientific Inc., and others.

(Albany, USA) DelveInsight’s “Lymphangioleiomyomatosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lymphangioleiomyomatosis, historical and forecasted epidemiology as well as the Lymphangioleiomyomatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Lymphangioleiomyomatosis, offering comprehensive insights into the Lymphangioleiomyomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Lymphangioleiomyomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Lymphangioleiomyomatosis therapies. Additionally, we cover the landscape of Lymphangioleiomyomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Lymphangioleiomyomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Lymphangioleiomyomatosis space.

 

To Know in detail about the Lymphangioleiomyomatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lymphangioleiomyomatosis Market Forecast

 

Some of the key facts of the Lymphangioleiomyomatosis Market Report:

  • The Lymphangioleiomyomatosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Key Lymphangioleiomyomatosis Companies: Apotex Inc., Amneal Pharmaceuticals LLC, Dr. Reddy’s Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Zydus Pharmaceuticals, Inc, TransMedics, Inc., Terumo Corporation, Home Oxygen Company, Inogen, Inc., CareDx, XVIVO, Taj Pharmaceuticals Limited, Morgan Scientific Inc., and others.
  • Key Lymphangioleiomyomatosis Therapies: Everolimus (RAD001), RAD001, and others
  • The Lymphangioleiomyomatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lymphangioleiomyomatosis pipeline products will significantly revolutionize the Lymphangioleiomyomatosis market dynamics.
  • Rare disease, primarily affecting women of childbearing age, typically between 20 and 40 years old
  • The estimated prevalence of LAM is approximately 3–8 cases per million women worldwide
  • LAM can occur sporadically (sporadic LAM) or in association with tuberous sclerosis complex (TSC-LAM)
  • Sporadic LAM accounts for about 80–90% of all LAM cases
  • TSC-LAM is observed in around 30–40% of women with tuberous sclerosis complex

 

Lymphangioleiomyomatosis Overview

Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women, usually during their childbearing years. It is characterized by the abnormal growth of smooth muscle-like cells in the lungs, lymphatic system, and kidneys, leading to lung cysts, airway obstruction, and respiratory issues. Over time, LAM can cause breathing difficulties, lung collapse (pneumothorax), and reduced lung function. It can occur sporadically or in association with a genetic condition called tuberous sclerosis complex (TSC).

 

Get a Free sample for the Lymphangioleiomyomatosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/lymphangioleiomyomatosis-market

 

Lymphangioleiomyomatosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Lymphangioleiomyomatosis Epidemiology Segmentation:

The Lymphangioleiomyomatosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Lymphangioleiomyomatosis
  • Prevalent Cases of Lymphangioleiomyomatosis by severity
  • Gender-specific Prevalence of Lymphangioleiomyomatosis
  • Diagnosed Cases of Episodic and Chronic Lymphangioleiomyomatosis

 

Download the report to understand which factors are driving Lymphangioleiomyomatosis epidemiology trends @ Lymphangioleiomyomatosis Epidemiology Forecast

 

Lymphangioleiomyomatosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lymphangioleiomyomatosis market or expected to get launched during the study period. The analysis covers Lymphangioleiomyomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lymphangioleiomyomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Lymphangioleiomyomatosis Therapies and Key Companies

  • Everolimus (RAD001): Novartis
  • RAD001: Children’s Hospital Medical Center, Cincinnati

 

Discover more about therapies set to grab major Lymphangioleiomyomatosis market share @ Lymphangioleiomyomatosis Treatment Landscape

 

Lymphangioleiomyomatosis Market Drivers

  • Increased awareness and early diagnosis of rare diseases including LAM through patient advocacy and physician education
  • Advancements in genetic research and identification of TSC mutations linked to LAM have enhanced diagnostic accuracy
  • Emerging targeted therapies such as mTOR inhibitors (e.g., sirolimus) have shown promising results in managing symptoms and slowing disease progression
  • Supportive regulatory frameworks (e.g., Orphan Drug Designation) encourage the development of treatments for rare diseases like LAM

 

Lymphangioleiomyomatosis Market Barriers

  • Low disease prevalence limits commercial interest and investment from major pharmaceutical companies
  • Delayed diagnosis due to nonspecific symptoms often misdiagnosed as asthma or COPD
  • Limited treatment options currently available, with no definitive cure for the disease
  • High cost of therapy and long-term care poses economic challenges for both patients and healthcare systems
  • Lack of large-scale clinical trials due to difficulty in recruiting sufficient patient populations for a rare condition

 

Scope of the Lymphangioleiomyomatosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Lymphangioleiomyomatosis Companies: Apotex Inc., Amneal Pharmaceuticals LLC, Dr. Reddy’s Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Zydus Pharmaceuticals, Inc, TransMedics, Inc., Terumo Corporation, Home Oxygen Company, Inogen, Inc., CareDx, XVIVO, Taj Pharmaceuticals Limited, Morgan Scientific Inc., and others.
  • Key Lymphangioleiomyomatosis Therapies: Everolimus (RAD001), RAD001, and others
  • Lymphangioleiomyomatosis Therapeutic Assessment: Lymphangioleiomyomatosis current marketed and Lymphangioleiomyomatosis emerging therapies
  • Lymphangioleiomyomatosis Market Dynamics: Lymphangioleiomyomatosis market drivers and Lymphangioleiomyomatosis market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Lymphangioleiomyomatosis Unmet Needs, KOL’s views, Analyst’s views, Lymphangioleiomyomatosis Market Access and Reimbursement

 

To know more about Lymphangioleiomyomatosis companies working in the treatment market, visit @ Lymphangioleiomyomatosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Lymphangioleiomyomatosis Market Report Introduction

2. Executive Summary for Lymphangioleiomyomatosis

3. SWOT analysis of Lymphangioleiomyomatosis

4. Lymphangioleiomyomatosis Patient Share (%) Overview at a Glance

5. Lymphangioleiomyomatosis Market Overview at a Glance

6. Lymphangioleiomyomatosis Disease Background and Overview

7. Lymphangioleiomyomatosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Lymphangioleiomyomatosis

9. Lymphangioleiomyomatosis Current Treatment and Medical Practices

10. Lymphangioleiomyomatosis Unmet Needs

11. Lymphangioleiomyomatosis Emerging Therapies

12. Lymphangioleiomyomatosis Market Outlook

13. Country-Wise Lymphangioleiomyomatosis Market Analysis (2019–2032)

14. Lymphangioleiomyomatosis Market Access and Reimbursement of Therapies

15. Lymphangioleiomyomatosis Market Drivers

16. Lymphangioleiomyomatosis Market Barriers

17. Lymphangioleiomyomatosis Appendix

18. Lymphangioleiomyomatosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lymphangioleiomyomatosis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

Cough in Idiopathic Pulmonary Fibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Cough in Idiopathic Pulmonary Fibrosis Clinical Trials”
Cough in Idiopathic Pulmonary Fibrosis companies are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others

(Albany, United States) As per DelveInsight’s assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for sample report to know in detail about the emerging therapies @ Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight

 

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:

  • Cough in IPF Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
  • Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment.
  • Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.
  • In March 2025, Trevi Therapeutics, the U.S.-based company developing nalbuphine extended-release (ER) tablets, announced the completion of enrollment in the Phase 2b clinical trial, known as CORAL. The trial is evaluating the therapy, which is intended to be marketed as Haduvio, in individuals with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. This milestone marks a significant step forward in the development of Haduvio for IPF patients dealing with chronic cough.
  • In February 2025, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced the completion of patient enrollment in its Phase 2b CORAL trial evaluating Haduvio for chronic cough in IPF patients.
  • In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel, first-in-class human IgG1 antibody aimed at inhibiting WISP1-mediated fibrotic signaling, which plays a role in multiple debilitating diseases.
  • In December 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing the investigational treatment Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced a positive result from the planned sample size re-estimation (SSRE) for its ongoing Phase 2b CORAL trial in IPF patients with chronic cough. The outcome indicates that no adjustments are needed to the current sample size for the trial (N=160).
  • In August 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced that the majority of the 60 planned sites for the Phase 2b CORAL trial have been initiated. The trial, which aims to enroll around 160 patients, will include a sample size re-estimation (SSRE) in the fourth quarter of this year, once 50% of patients are evaluable for the primary endpoint. Barring any adjustments, topline results are expected in the first half of 2025.
  • In May 2024, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has announced topline results from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital. The trial evaluated changes in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF), a condition marked by excessive collagen buildup in the lungs.
  • In March 2024, US-based Seyltx finalized an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.

 

Cough in Idiopathic Pulmonary Fibrosis Overview

Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common and distressing symptom of this chronic lung disease. IPF causes scarring and thickening of the lung tissue, leading to breathing difficulties and persistent dry, non-productive cough. The exact cause of cough in IPF is not fully understood, but it is believed to result from the irritation caused by the fibrosis (scarring) of the lung tissue, which can trigger the cough reflex. This cough is often persistent, worsening over time, and can significantly impact a patient’s quality of life. Treatment typically focuses on managing symptoms and slowing the progression of IPF.

 

Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight

 

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

  • Orvepitant Maleate: NeRRe Therapeutics
  • Haduvio (nalbuphine ER): Trevi Therapeutics
  • ME-015 (Suplatast Tosilate): Melius Pharma AB
  • BI 1839100: Boehringer Ingelheim

 

Cough in Idiopathic Pulmonary Fibrosis Route of Administration

Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Cough in Idiopathic Pulmonary Fibrosis Molecule Type

Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

  • Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type
  • Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type
  • Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
  • Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
  • Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
  • Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

 

DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies

 

Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are – Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others

 

Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
  • Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies

 

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

  • High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.

 

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

  • However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.

 

Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

  • Coverage: Global
  • Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others
  • Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others
  • Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
  • Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers

 

Request for Sample PDF Report for Cough in Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Cough in Idiopathic Pulmonary Fibrosis Report Introduction

2. Cough in Idiopathic Pulmonary Fibrosis Executive Summary

3. Cough in Idiopathic Pulmonary Fibrosis Overview

4. Cough in Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Cough in Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Cough in Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Cough in Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Cough in Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Cough in Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cough in Idiopathic Pulmonary Fibrosis Key Companies

14. Cough in Idiopathic Pulmonary Fibrosis Key Products

15. Cough in Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Cough in Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Cough in Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cough in Idiopathic Pulmonary Fibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Severe Atopic Dermatitis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

“Severe Atopic Dermatitis Treatment Market”
Severe Atopic Dermatitis Companies are Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others.

(Albany, USA) DelveInsight’s “Severe Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Severe Atopic Dermatitis, historical and forecasted epidemiology as well as the Severe Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Bile Duct Neoplasm market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bile Duct Neoplasm market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Bile Duct Neoplasm treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Bile Duct Neoplasm market.

 

To Know in detail about the Severe Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Atopic Dermatitis Market Forecast

 

Some of the key facts of the Severe Atopic Dermatitis Market Report:

  • The Severe Atopic Dermatitis market size was valued ~USD 10,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In June 2025, Pfizer announced results of a Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis
  • In June 2025, Aclaris Therapeutics, Inc. announced results of a Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis
  • In April 2025, Keymed Biosciences Co.Ltd announced results of a Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
  • In January 2025, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has released new interim data from its randomized, double-blind, placebo-controlled Phase 1 trial assessing soquelitinib in patients with moderate to severe atopic dermatitis. The findings, which include previously reported results from cohort 1 and new data from 10 patients with a 28-day follow-up in cohort 2, demonstrated a strong safety and efficacy profile. Notably, the soquelitinib treatment groups showed significant improvements over placebo in key clinical endpoints, including IGA (Investigator Global Assessment) 0 or 1 and EASI (Eczema Area and Severity Index) 75.
  • In December 2024, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced interim results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe Severe Atopic Dermatitis. The findings revealed a positive safety and efficacy profile, bolstering the continued development of soquelitinib for Severe Atopic Dermatitis and highlighting the potential of ITK inhibition as a new therapeutic approach for other immune-related diseases.
  • In November 2024, Concerto Biosciences administered the first dose in a Phase I trial of its three-strain live biotherapeutic product, ENS-002, designed to treat Severe Atopic Dermatitis. ENS-002 targets Staphylococcus aureus (S. aureus), a major contributor to skin inflammation, and is being developed to address this condition.
  • In October 2024, Eli Lilly’s EBGLYSS showed significant improvement in skin condition and itch relief for patients with moderate-to-severe Severe Atopic Dermatitis, as highlighted by new Phase IIIb ADapt study results. These outcomes are particularly notable for individuals who did not respond adequately to the commonly prescribed dupilumab. The 24-week, open-label Phase IIIb ADapt study evaluated the safety and efficacy of EBGLYSS in patients aged 12 to under 18 years who had previously received dupilumab treatment.
  • In September 2024, Galderma has announced plans to present new findings from the ARCADIA and OLYMPIA clinical trial programs, which evaluate nemolizumab for Severe Atopic Dermatitis and prurigo nodularis, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam. Scheduled for Wednesday, September 25, the presentations will include late-breaking data on long-term efficacy and safety from an interim analysis of the Phase III ARCADIA long-term extension study and novel biomarker analyses in adolescents and adults with moderate-to-severe Severe Atopic Dermatitis. Additionally, Phase IIIb OLYMPIA DURABILITY study results showcasing the durability of nemolizumab’s response in adults with prurigo nodularis will also be shared.
  • In August 2024, Lynk Pharmaceuticals announced promising results from its Phase Ib clinical trial of LNK01004, a novel topical therapy for Severe Atopic Dermatitis. This randomized, double-blind, placebo-controlled, multicenter study evaluated the safety, tolerability, and pharmacokinetics of LNK01004 in adults with mild to moderate Severe Atopic Dermatitis.
  • In the 7MM, the United States had the largest market size for Severe Atopic Dermatitis in 2023, with Japan following closely behind.
  • DUPIXENT, the first approved therapy for Severe Atopic Dermatitis (AD), generates around USD 2 billion in revenue by focusing on the moderate-to-severe patient group through targeted therapies and biologics.
  • In 2023, there were approximately 53,348,000 diagnosed cases of Severe Atopic Dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.
  • In 2023, there were approximately 72,435,000 prevalent cases of Severe Atopic Dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.
  • In 2023, the total diagnosed cases of Severe Atopic Dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.
  • Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
  • Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
  • The Severe Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Atopic Dermatitis pipeline products will significantly revolutionize the Severe Atopic Dermatitis market dynamics.

 

Severe Atopic Dermatitis Overview

Severe atopic dermatitis (AD), a chronic inflammatory skin disorder, is characterized by intense itching, widespread erythema, and lichenification that significantly impairs quality of life. It is the most severe form of eczema, often resistant to standard topical therapies and requiring systemic treatment. The condition typically arises from a combination of genetic predisposition, immune dysregulation, and environmental triggers. Patients with severe AD often have elevated serum IgE levels and a personal or family history of atopy, including asthma and allergic rhinitis.

The disease presents with persistent, extensive lesions affecting large body areas such as the face, neck, limbs, and trunk. Constant scratching can lead to skin thickening, secondary infections (e.g., Staphylococcus aureus), and sleep disturbances. In children and adults alike, severe AD is associated with significant psychosocial burden, including anxiety and depression.

Management of severe atopic dermatitis involves a multidisciplinary approach, including intensive skin hydration, topical corticosteroids or calcineurin inhibitors, and phototherapy. Systemic agents such as oral corticosteroids, cyclosporine, methotrexate, and biologics like dupilumab have revolutionized treatment, offering targeted relief. Emerging therapies focusing on IL-13, IL-31, and JAK pathways are under investigation. Early diagnosis, regular monitoring, and patient education are vital in improving outcomes and long-term disease control.

 

Get a Free sample for the Severe Atopic Dermatitis Market Report: https://www.delveinsight.com/report-store/severe-atopic-dermatitis-market

 

Severe Atopic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Severe Atopic Dermatitis Epidemiology Segmentation:

The Severe Atopic Dermatitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Severe Atopic Dermatitis
  • Prevalent Cases of Severe Atopic Dermatitis by severity
  • Gender-specific Prevalence of Severe Atopic Dermatitis
  • Diagnosed Cases of Episodic and Chronic Severe Atopic Dermatitis

 

Download the report to understand which factors are driving Severe Atopic Dermatitis epidemiology trends @ Severe Atopic Dermatitis Epidemiology Forecast

 

Severe Atopic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Severe Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Severe Atopic Dermatitis Therapies and Key Companies

  • Bermekimab: Janssen Pharmaceutical
  • FB825: Oneness Biotech
  • Lebrikizumab: Eli Lily
  • Nemolizumab: Galderma
  • B244: AOBiome
  • Ruxolitinib: Incyte
  • Difelikefalin: Cara Therapeutics
  • Roflumilast: Arcutis Biotherapeutics
  • Rocatinlimab: Amgen/Kyowa Kirin
  • Tapinarof: Dermavant Sciences
  • KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics
  • Etrasimod: Pfizer/Arena pharmaceuticals
  • BMX-010: BioMimetix

 

Discover more about therapies set to grab major Severe Atopic Dermatitis market share @ Severe Atopic Dermatitis Treatment Market

 

Severe Atopic Dermatitis Market Drivers

  • Rising prevalence of Severe Atopic Dermatitis
  • Escalating expenditure on healthcare
  • Approvals of JAK inhibitors
  • Potential Emerging Therapies for Severe Atopic Dermatitis and pruritus
  • Increasing awareness about the condition

 

Severe Atopic Dermatitis Market Barriers

  • Over-the-counter medications
  • Outdated treatment recommendations
  • Poor prognosis and treatment adherence
  • Lack of timely diagnosis
  • Management of Severe Atopic Dermatitis in the primary care setting

 

Scope of the Severe Atopic Dermatitis Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
  • Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
  • Severe Atopic Dermatitis Therapeutic Assessment: Severe Atopic Dermatitis current marketed and Severe Atopic Dermatitis emerging therapies
  • Severe Atopic Dermatitis Market Dynamics: Severe Atopic Dermatitis market drivers and Severe Atopic Dermatitis market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Severe Atopic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Severe Atopic Dermatitis Market Access and Reimbursement

 

To know more about Severe Atopic Dermatitis companies working in the treatment market, visit @ Severe Atopic Dermatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Severe Atopic Dermatitis Market Report Introduction

2. Executive Summary for Severe Atopic Dermatitis

3. SWOT analysis of Severe Atopic Dermatitis

4. Severe Atopic Dermatitis Patient Share (%) Overview at a Glance

5. Severe Atopic Dermatitis Market Overview at a Glance

6. Severe Atopic Dermatitis Disease Background and Overview

7. Severe Atopic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Atopic Dermatitis

9. Severe Atopic Dermatitis Current Treatment and Medical Practices

10. Severe Atopic Dermatitis Unmet Needs

11. Severe Atopic Dermatitis Emerging Therapies

12. Severe Atopic Dermatitis Market Outlook

13. Country-Wise Severe Atopic Dermatitis Market Analysis (2020–2034)

14. Severe Atopic Dermatitis Market Access and Reimbursement of Therapies

15. Severe Atopic Dermatitis Market Drivers

16. Severe Atopic Dermatitis Market Barriers

17. Severe Atopic Dermatitis Appendix

18. Severe Atopic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Severe Atopic Dermatitis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

Axillary Hyperhidrosis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

“Axillary Hyperhidrosis Treatment Market”
Alopecia Areata Companies are Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others.

(Albany, USA) DelveInsight’s “Axillary Hyperhidrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Axillary Hyperhidrosis, historical and forecasted epidemiology as well as the Axillary Hyperhidrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Axillary Hyperhidrosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Axillary Hyperhidrosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Axillary Hyperhidrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Axillary Hyperhidrosis market.

 

To Know in detail about the Axillary Hyperhidrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axillary Hyperhidrosis Market Forecast

 

Some of the key facts of the Axillary Hyperhidrosis Market Report:

  • The Axillary Hyperhidrosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In February 2025, Dermata Therapeutics, Inc. (NASDAQ: DRMA, DRMAW), a late-stage biotechnology company specializing in medical and aesthetic skin conditions, announced that the Australian Patent Office has accepted its patent application for the DMT410 program targeting hyperhidrosis. The patent, titled “Compositions for the Treatment of Skin Conditions” (Australian Patent Application No. 2109284621), further enhances Dermata’s global intellectual property portfolio for DMT410. Unless opposed by a third party, the patent will be officially granted three months after acceptance.
  • In June 2024, Botanix Pharmaceuticals announced that it has received approval from the US Food and Drug Administration (FDA) for Sofdra (sofpironium) gel, 12.45%, for the treatment of excessive underarm sweating (primary axillary hyperhidrosis). The treatment is approved for use in adults and children aged nine years and older. Sofdra is the first and only new chemical entity to be approved in the US for this condition.
  • In January 2024, InMode MD Ltd. offers the InMode Pro System with the Morpheus8 Applicator, a computerized device that produces radio frequency energy utilizing Fractional RF technology. The Morpheus8 Applicator, equipped with a 24-pin tip, is specifically designed for treating primary hyperhidrosis in the underarm area.
  • In 2022, the Axillary Hyperhidrosis market in the US recorded the highest size, reaching around USD 500 million, and is projected to grow further by 2032.
  • In the US, the estimated prevalence of Axillary Hyperhidrosis is 2.8%, affecting approximately 7.8 million individuals. Among them, 50.8% (around 4.0 million people or 1.4% of the US population) reported experiencing axillary hyperhidrosis.
  • There are currently too few and insufficient epidemiologic data on hyperhidrosis to establish accurate prevalence or impact estimates. According to DelveInsight analysts, there were 10,491,560 cases of axillary hyperhidrosis (AH) in the US as a whole
  • Based on the HDSS scale, the degree of axillary hyperhidrosis was assessed. According to DelveInsight, 1,584,618 people had non-severe symptoms and roughly 1,716,670 people had severe symptoms in 2021
  • In the US, there were 3,301,288 diagnosed cases of axillary hyperhidrosis (AH) overall in 2021.
  • The prevalence of primary axillary hyperhidrosis in the population of Japan aged 5-64 years is 5.75% (males, 6.60%; females, 4.72%), according to a study by Murota et al. (2021).
  • Key Axillary Hyperhidrosis Companies: Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others
  • Key Axillary Hyperhidrosis Therapies: Sofpironium Bromide, VASE, Glycopyrronium Bromide, Meditoxin, glycopyrronium Topical Wipesl, and others
  • The Axillary Hyperhidrosis epidemiology based on gender analyzed that in the US, out of the total diagnosed cases of Axillary Hyperhidrosis in 2021, 93% accounted for primary hyperhidrosis and 7% accounted for secondary hyperhidrosis
  • The Axillary Hyperhidrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axillary Hyperhidrosis pipeline products will significantly revolutionize the Axillary Hyperhidrosis market dynamics.

 

Axillary Hyperhidrosis Overview

Axillary hyperhidrosis is a medical condition characterized by excessive sweating in the underarm (axillary) area. This condition goes beyond the normal sweating that helps regulate body temperature and can be persistent and unpredictable. People with axillary hyperhidrosis often experience significant discomfort and embarrassment due to the constant wetness, which can interfere with daily activities, social interactions, and overall quality of life.

 

Get a Free sample for the Axillary Hyperhidrosis Market Report: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market

 

Axillary Hyperhidrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Axillary Hyperhidrosis Epidemiology Segmentation:

The Axillary Hyperhidrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Axillary Hyperhidrosis
  • Prevalent Cases of Axillary Hyperhidrosis by severity
  • Gender-specific Prevalence of Axillary Hyperhidrosis
  • Diagnosed Cases of Episodic and Chronic Axillary Hyperhidrosis

 

Download the report to understand which factors are driving Axillary Hyperhidrosis epidemiology trends @ Axillary Hyperhidrosis Epidemiology Forecast

 

Axillary Hyperhidrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axillary Hyperhidrosis market or expected to get launched during the study period. The analysis covers Axillary Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Axillary Hyperhidrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Axillary Hyperhidrosis Therapies and Key Companies

  • Sofpironium bromide (BBI-4000): Botanix Pharma
  • VASER: Sound Surgical Technologies, LLC.
  • Glycopyrronium Bromide: Dr. August Wolff GmbH
  • Meditoxin: Medy-Tox
  • glycopyrronium Topical Wipes: Journey Medical Corporation

 

Discover more about therapies set to grab major Axillary Hyperhidrosis market share @ Axillary Hyperhidrosis Treatment Market

 

Scope of the Axillary Hyperhidrosis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Axillary Hyperhidrosis Companies: Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others
  • Key Axillary Hyperhidrosis Therapies: Sofpironium Bromide, VASE, Glycopyrronium Bromide, Meditoxin, glycopyrronium Topical Wipes, and others
  • Axillary Hyperhidrosis Therapeutic Assessment: Axillary Hyperhidrosis current marketed and Axillary Hyperhidrosis emerging therapies
  • Axillary Hyperhidrosis Market Dynamics: Axillary Hyperhidrosis market drivers and Axillary Hyperhidrosis market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Axillary Hyperhidrosis Unmet Needs, KOL’s views, Analyst’s views, Axillary Hyperhidrosis Market Access and Reimbursement

 

To know more about Axillary Hyperhidrosis companies working in the treatment market, visit @ Axillary Hyperhidrosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Axillary Hyperhidrosis Market Report Introduction

2. Executive Summary for Axillary Hyperhidrosis

3. SWOT analysis of Axillary Hyperhidrosis

4. Axillary Hyperhidrosis Patient Share (%) Overview at a Glance

5. Axillary Hyperhidrosis Market Overview at a Glance

6. Axillary Hyperhidrosis Disease Background and Overview

7. Axillary Hyperhidrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Axillary Hyperhidrosis

9. Axillary Hyperhidrosis Current Treatment and Medical Practices

10. Axillary Hyperhidrosis Unmet Needs

11. Axillary Hyperhidrosis Emerging Therapies

12. Axillary Hyperhidrosis Market Outlook

13. Country-Wise Axillary Hyperhidrosis Market Analysis (2019–2032)

14. Axillary Hyperhidrosis Market Access and Reimbursement of Therapies

15. Axillary Hyperhidrosis Market Drivers

16. Axillary Hyperhidrosis Market Barriers

17. Axillary Hyperhidrosis Appendix

18. Axillary Hyperhidrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Axillary Hyperhidrosis Treatment Market 2032: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

Professional Services Automation by IBN Technologies Enhances Workflow Precision in U.S. Healthcare Systems

“Professional Services Automation [USA]”
U.S. hospitals are transforming finance operations by shifting to professional services automation. With AI and automation, providers improve claims accuracy, reduce manual work, and gain visibility into complex financial cycles. Digital experts like IBN Technologies deliver tailored solutions that help hospitals run smarter, scale faster, and maintain compliance.

Miami, Florida, 04 Aug 2025 Healthcare providers in the U.S. are advancing operational strategies that prioritize both care quality and administrative accuracy. Financial leaders within hospitals and specialty care facilities are focusing on scalable systems that support long-term stability. A key development in this space is the application of professional services automation, which is helping streamline revenue workflows and improve how billing and insurance data is processed.

As the demand grows for more structured financial oversight, organizations are implementing automated financial services to manage multi-location accounting and improve reconciliation. This move enables faster transaction tracking and fewer delays in payment cycles. In response to these operational needs, companies like IBN Technologies have stepped in to offer digital infrastructure that reinforces control and precision across the financial arm of healthcare enterprises.

Replace delays with consistent, automated processing

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-ipa/

Hospitals Confront Billing Inefficiencies

Financial pressure continues to mount for U.S. healthcare providers as inflation raises the cost of operations. Labor shortages, supply pricing, and high patient volume are exposing weaknesses in manual billing. Administrative teams are under pressure to keep pace without streamlined systems.

▪ Lag in managing multi-payer reimbursements

▪ High error rates in manual data inputs

▪ Staff fatigue due to transactional workload

▪ Slow response in claims reconciliation

▪ Incomplete payment tracking systems

▪ Gaps in audit-readiness and documentation

▪ Delayed reporting across departments

▪ Rising compliance risks under manual oversight

To counter these breakdowns, healthcare groups are working with finance automation experts to redesign core processes. Digital specialists are equipping hospitals with solutions that improve accuracy, speed, and internal coordination. Through professional services automation, providers are building reliable workflows for billing and receivables—resulting in better oversight, faster claim processing, and lower burden on staff.

Healthcare Workflow Automation Benefits

Rising patient volume, complex billing structures, and staffing shortages are prompting healthcare leaders to rethink how they manage administrative systems. Rather than overloading internal teams, decision-makers are turning to automation experts to simplify and secure financial operations.

✅ Patient invoicing automation with insurer-specific claim routing support

✅ Revenue cycle systems built for financial transparency and accuracy

✅ Instant payer validation paired with authorization integration tools

✅ Charge posting automation linked to health record systems directly

✅ Unified dashboard for real-time reconciliation and payment alerts

✅ Denials and reprocessing workflows designed for provider scalability

✅ Automated benefit checks and accurate co-pay estimation flows

✅ Intelligent AR collections handled by automated prioritization logic

✅ HIPAA-compliant records stored via encrypted audit management systems

✅ Smart scheduling paired with task-based financial automation modules

Healthcare leaders are increasingly relying on structured partners to manage financial systems with agility and insight. Firms like IBN Technologies offer expert-driven services through professional services automation in Arizona, enabling providers to navigate complex finance environments with consistency, compliance, and operational focus.

Arizona Healthcare Automation Yields Results

In Arizona, a major healthcare organization reported clear operational improvements after implementing digital automation within its finance and billing infrastructure. Supported by external specialists, the system was reengineered to reduce delays and bring greater visibility into administrative cycles.

  • Order entry processing time dropped from 7 minutes to just 2 minutes

  • Billing-related errors decreased significantly, improving data consistency

  • More than 80% of all financial activity now runs via automation

  • End-to-end accountability and visibility were established at every location

This advancement reflects the tangible results healthcare groups are realizing in Arizona when manual processes are replaced with streamlined solutions. With the integration of professional services automation, financial accuracy, compliance alignment, and operational stability have become attainable for providers managing complex patient care systems.

Healthcare Finance Enters Predictive Era

Healthcare providers in the U.S. are under growing pressure to optimize financial performance without burdening clinical operations. With reimbursement models becoming increasingly complex, organizations are prioritizing process efficiency and accuracy to sustain revenue health. Many have begun reassessing how billing, claims reconciliation, and administrative tasks are managed—shifting away from fragmented workflows toward centralized, intelligent systems.

This evolution is now being driven by the strategic adoption of AI and automation. Hospitals and multi-site health networks are implementing structured systems to reduce time-consuming tasks, cut down on billing errors, and improve visibility across finance operations. Through professional services automation, providers are transitioning from manual execution to high-performing digital frameworks. Experts like IBN Technologies are supporting this shift by delivering solutions that align with provider needs, system interoperability, and compliance benchmarks. The result is not just smoother workflows—it’s a redefined approach to financial operations that scales with healthcare delivery.

Related Services:                

  1. Invoice Processing Automation: https://www.ibntech.com/invoice-process-automation/    

  2. Medical Claim Automation: https://www.ibntech.com/medical-claim-automation/         

About IBN Technologies                 

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Professional Services Automation by IBN Technologies Enhances Workflow Precision in U.S. Healthcare Systems

USA Healthcare Providers Adopt Professional Services Automation with IBN Technologies for Operational Gains

“Professional Services Automation [USA]”
This news highlights the growing adoption of professional services automation within the U.S. healthcare industry. Readers will learn how healthcare providers are improving billing accuracy, accelerating revenue cycles, and reducing administrative burdens. The integration of AI and automation tools is driving scalable, compliant financial operations. Insights reveal how expert solutions are shaping future-ready healthcare workflows and decision-making.

Miami, Florida, 04 Aug 2025 Healthcare providers in the U.S. are actively adopting streamlined financial models that improve care delivery without compromising administrative accuracy. As revenue cycles become more complex, many hospitals and specialty clinics are investing in customized outsourcing strategies to improve backend efficiency. Among these, professional services automation is becoming a key component in modernizing how healthcare finance teams manage billing, receivables, and insurance reconciliation workflows.

Process automation is enabling providers to centralize multi-entity accounting and enhance the visibility of financial transactions without increasing overhead. Service-based healthcare organizations are now aligning their outsourcing goals with long-term operational success, using intelligent systems to structure payment timelines and reduce the manual workload on in-house teams. This structured shift has helped various outpatient and surgical care centers stabilize their billing cycles and achieve improved accuracy in collections. The momentum is moving toward outcome-based efficiency models, where service partners are expected to deliver streamlined processes that fit both the payer and provider sides of the business. In this environment, automated financial services aren’t just about reducing delays—they are defining a new benchmark for how U.S. healthcare groups operate under pressure while meeting compliance and scalability targets.

Power your payables through automation.

Get a Free Consultation: https://www.ibntech.com/free-consultation-for-ipa/

Manual Billing Faces Pressure

Rising operational costs in the U.S. healthcare sector have intensified scrutiny on outdated manual finance processes. With inflation driving up labor and supply chain expenses, hospitals and care providers are facing additional stress in managing billing and receivables manually, without structured automation in place.

▪ Inefficiencies in handling high-volume patient claims

▪ Delays in reconciling multi-insurer reimbursements

▪ Increased error rates during data entry and charge capture

▪ Staff burnout from repetitive financial tasks

▪ Difficulty tracking outstanding payments in real-time

▪ Limited transparency in billing and audit preparation

▪ Slower turnaround in generating accurate reports

▪ Higher risk of compliance gaps in manual documentation

As these challenges continue to impact the revenue cycle, many healthcare organizations are actively seeking expert-backed solutions to build sustainable operational models. Service partners specializing in healthcare finance now support providers with structured workflows, customized strategies, and integrated systems that align with their growth. Professional services automation has emerged as a reliable support system, helping hospitals and clinics handle financial operations with greater consistency and reduced delays, without adding administrative burden to frontline teams.

Healthcare Gains with Automation

Hospitals and healthcare providers in the U.S. are steadily turning to structured outsourcing models to reduce administrative delays and improve financial accuracy. Decision-makers are aligning with specialists who serve professional services automation, building a foundation for consistent billing, real-time reporting, and scalable support.

✅ Automated patient billing and multi-insurer claim submission workflows

✅ End-to-end revenue cycle automation with integrated financial visibility

✅ Real-time insurance verification and prior authorization solutions

✅ Electronic health record integration with automated charge posting tools

✅ Centralized payment reconciliation with dynamic dashboard access

✅ Denial tracking and resolution workflows are configured for healthcare systems

✅ Automated patient eligibility checks and co-pay estimate generation

✅ Streamlined AR collection services through intelligent task routing

✅ Secure document management for audits and HIPAA compliance

✅ Scheduling and financial task automation across medical departments

Executives in the healthcare sector are actively streamlining finance processes to reduce costs, boost accuracy, and improve staff productivity. With the guidance of outsourced service providers offering professional services automation in the USA, many care networks are seeing strong operational returns. These firms combine automation with tailored strategies, allowing healthcare providers to function with efficiency, consistency, and compliance in mind while remaining focused on care delivery.

Proven Impact on Healthcare Automation

A leading healthcare network in the United States improved its financial operations through advanced automation strategies guided by expert service providers. By integrating automated workflows into their EHR and billing platforms, the organization achieved measurable results in accuracy, efficiency, and system-wide oversight.

  • Order entry time was reduced by two-thirds, going from 7 minutes to 2 minutes.

  • Error rates in billing operations dropped significantly, boosting accuracy levels throughout the network.

  • Over 80% of financial transactions are now processed automatically across all locations.

  • Full visibility and responsibility tracking were established, ensuring 100% operational accountability.

These outcomes highlight how professional services automation is transforming healthcare administration in the USA—creating structured, accurate, and scalable workflows that support both efficiency and long-term sustainability.

Healthcare Moves Toward Intelligent Systems

U.S. healthcare providers are finalizing automation strategies that align with revenue goals, workforce stability, and compliance expectations. Industry professionals are increasingly implementing professional services automation to simplify complex workflows, improve billing accuracy, and reduce operational pressure. This shift reflects a broader move toward structured digital adoption—where measurable improvements are now guiding strategic decisions.

By integrating AI and Automation into core financial operations, medical facilities are achieving stronger visibility, improved turnaround times, and more scalable patient service models. Administrators report enhanced decision-making through predictive systems, while finance teams benefit from reduced manual load and greater reporting consistency. These outcomes position automation not just as a support function, but as a strategic asset shaping the future of U.S. healthcare infrastructure. Firms like IBN Technologies are leading this transformation, offering expert-driven solutions that connect seamlessly with ERP systems and deliver personalized automation frameworks. With clear results emerging from early adopters, healthcare organizations are choosing structured, expert-backed services to build resilient, future-ready workflows.

Related Services:               

  1. Invoice Processing Automation: https://www.ibntech.com/invoice-process-automation/   

  2. Medical Claim Automation: https://www.ibntech.com/medical-claim-automation/        

About IBN Technologies                

IBN Technologies LLC, an outsourcing specialist with 26 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.                

 

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: USA Healthcare Providers Adopt Professional Services Automation with IBN Technologies for Operational Gains

Smart Pumps Market to Reach USD 1.24 Billion by 2030, Driven by Increasing Demand from Oil & Gas and Water Treatment Industries – Mordor Intelligence

“Smart Pumps Market”
Mordor Intelligence has published a new report on the Smart Pumps Market offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

According to a 2025 report on the smart pumps market by Mordor Intelligence, the market size is projected to grow from USD 0.86 billion in 2025 to USD 1.24 billion by 2030, at a CAGR of 7.59% during the forecast period. This growth is supported by the rising adoption of energy-efficient pump systems and increasing investments in industrial automation across end-user industries such as water treatment, chemicals, oil and gas, and power generation.

The smart pumps market refers to a segment of the global pump industry that integrates advanced digital technologies such as sensors, control systems, and connectivity features into traditional pumping equipment. These pumps are designed to automatically monitor, regulate, and optimize their performance based on real-time operating conditions. Unlike conventional pumps, smart pumps can adjust flow rates, detect system faults, and provide usage analytics, making them more efficient and reliable.

 

Key Market Trends in the Smart Pumps Market

Increasing Adoption in Water and Wastewater Treatment

Governments and municipalities are investing in smart water infrastructure. Smart pumps help monitor flow, pressure, and energy use, improving system reliability and reducing water loss.

Integration with IoT and Remote Monitoring Systems

Smart pumps are increasingly connected to cloud-based platforms and SCADA systems, allowing for real-time performance tracking, fault detection, and remote diagnostics.

Rising Focus on Energy Efficiency

Industries are prioritizing energy-saving technologies. Smart pumps, with variable speed drives and automated controls, help reduce energy consumption and operating costs.

Growing Use in Oil & Gas and Chemical Industries

These sectors demand precision and safety. Smart pumps support accurate flow control and provide early warnings for equipment issues, minimizing downtime and risk.

 

Market Segmentation

By Type

  • Centrifugal: Widely used for applications requiring high flow rates. Common in water, HVAC, and wastewater systems.

  • Positive Displacement: Suitable for precise flow control in industries like oil & gas, chemicals, and food processing.

 

By Capacity (m³/h)

  • Up to 30: Ideal for small-scale or precision applications such as dosing systems or compact HVAC setups.

  • 30 – 90: Common in medium-capacity systems like commercial buildings and municipal water systems.

  • 90 – 180: Used in mid-sized industrial applications with moderate flow needs.

  • 180 – 360: Suited for large-scale operations including desalination and flood control.

  • Above 360: Deployed in heavy-duty, continuous flow industries such as power generation and large water utilities.

 

By Connectivity

  • Wired (Ethernet, Fieldbus, HART): Traditional and widely adopted for integration into established industrial systems.

  • Wireless (Wi-Fi, Cellular, LPWAN): Gaining traction for remote monitoring, flexible deployment, and IoT integration in modern facilities.

 

By Component

  • Pump Hardware: Core mechanical system that handles fluid movement; dominant cost component.

  • Sensors and Instrumentation: Enable data collection on pressure, flow, and temperature for real-time control.

  • Variable-Frequency Drives (VFDs): Adjust motor speed to optimize energy use and system efficiency.

  • Control and Analytics Software: Provides system monitoring, diagnostics, and performance optimization through digital platforms.

 

By End-User

  • Building Automation: Used in HVAC and water systems to regulate temperature and energy use in commercial and residential structures.

  • Water and Wastewater: Major user segment deploying smart pumps for efficient and automated flow control in municipal infrastructure.

  • Oil and Gas: Requires smart pumping solutions for enhanced safety, remote monitoring, and optimized flow in extraction and processing.

  • Chemicals: Utilizes precision pumping for dosing and transfer in complex chemical manufacturing environments.

 

By Geography

  • North America: North America holds a considerable share in the smart pumps market, benefitting from mature industrial infrastructure, strong regulatory demand for energy efficiency, and rapid adoption of IoT-enabled systems. The region has established players and a favorable business environment that supports digital transformation in sectors such as water utilities, oil & gas, and commercial buildings

  • South America: While South America is not highlighted as a leading region in the Mordor report, growing industrial investment and water infrastructure upgrades suggest emerging interest in smart pump solutions, especially in municipal and agricultural sectors. Regional adoption is expected to pick up as energy and automation policies advance.

  • Europe: Europe is the largest region in the smart pumps market, accounting for roughly 29.5% of global revenue in 2024. The region’s leadership stems from strong energy-efficiency mandates (like Ecodesign regulations), public-sector investment in infrastructure, and progressive adoption of digital control systems for fluid handling operations

 

Major Players

Grundfos Holding A/S

Based in Denmark and founded in 1945, Grundfos is the world’s largest pump manufacturer with over 19,000 employees globally. The company offers smart pumps such as its E‑pumps, which combine energy-efficient motors, controllers, and sensors into a compact, integrated solution. These systems support real‑time monitoring and variable speed control to reduce energy use in building systems, water distribution, and industrial applications

Xylem Inc.

Xylem is a U.S.-based water technology company spun off from ITT Corporation in 2011. It operates globally in more than 150 countries, with reported 2024 revenue of around USD 8.6 billion and approximately 23,000 employees. Xylem provides smart pumping solutions for municipal water networks, wastewater, industrial fluid handling, and applied water systems. Through acquisitions like Evoqua (completed in 2023), Xylem has strengthened its position as a pure-play water technology leader

Sulzer Ltd.

Sulzer, founded in Switzerland in the 1800s, is a global industrial engineering firm with around CHF 3.3 billion in revenue (2023) and more than 13,000 employees. Through its Flow Equipment Services division, Sulzer delivers smart pump solutions tailored for demanding industries such as oil & gas, water treatment, and power generation emphasizing efficiency, remote monitoring, and reliability

Flowserve Corporation

Flowserve is a U.S.-based industrial machinery supplier headquartered in Texas. With roots going back to the 18th century, the modern Flowserve brand emerged in 1997 through mergers and acquisitions. It generated approximately USD 3.9 billion in revenue by 2019 and employs tens of thousands across more than 50 countries Flowserve offers smart pump products and systems often integrated with control, seal, and automation components that serve oil & gas, chemical, power, and water sectors.

Wilo SE

Wilo SE is a German company founded in 1872, specializing in pumps and pump systems for building services, water management, and industrial automation. With annual revenue of about EUR 1.9 billion in 2022 and approximately 9,000 employees in 2024, Wilo operates over 60 subsidiaries and produces around 10 million pump units each year. Its smart pump offerings include systems for HVAC, building automation, and smart water networks, often enhanced with AI‑based control and energy optimization features

 

Conclusion

The smart pumps market is gaining momentum as industries worldwide prioritize efficiency, automation, and predictive maintenance. With a projected CAGR of 8.29% between 2025 and 2030, the market is expanding steadily across sectors such as water and wastewater treatment, oil and gas, chemicals, power generation, and building automation.

Get More Insights: https://www.mordorintelligence.com/industry-reports/smart-pumps-market?utm_source=abnewswire

 

Industry Related Reports

Vacuum Pump Market : The Industrial Vacuum Pumps Market is categorized based on pump principle (including rotary, reciprocating, kinetic, dynamic, entrapment, cryogenic, getter, and ion types), lubrication type (dry vacuum pumps and oil-sealed/wet vacuum pumps), and vacuum level (rough/low, medium, high, and others). It is also segmented by end-user application, such as oil and gas, semiconductor and electronics, among others, and by geography. Market forecasts are presented in terms of value (USD).

 

Hydraulic Pumps Market: The Hydraulic Pumps Market is segmented by pump type (gear, vane, and others), operating pressure range (below 3,000 psi, 3,000–5,000 psi, and above 5,000 psi), and application (mobile hydraulics, industrial machinery, process and energy). It is further categorized by end-user verticals, including construction, oil and gas, and others, as well as by geography. Market forecasts are provided in terms of value (USD).

Get More Insights: https://www.mordorintelligence.com/industry-reports/hydraulic-pumps-market?utm_source=abnewswire

 

Smart implantable pumps market : The Smart Implantable Pumps Market report is segmented by pump type (including perfusion pumps, micro pumps, programmable insulin pumps, and others), application (such as pain management, spasticity management, cardiovascular disorders, and more), and end users (hospitals, ambulatory surgical centers, specialty clinics, and homecare settings). It is also categorized by geography, covering regions like North America, Europe, and others. Market forecasts are presented in terms of value (USD).

 

About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

 

For any inquiries or to access the full report, please contact:media@mordorintelligence.com

https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email: Send Email
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Pumps Market to Reach USD 1.24 Billion by 2030, Driven by Increasing Demand from Oil & Gas and Water Treatment Industries – Mordor Intelligence